- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02084511
Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain
Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain (a Single-centre, Partially Double-blinded, Randomised, placebo-and Active Comparator-controlled, Single-dose, Parallel-group Study)
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Verona, Italie
- 1320.13.39001 Boehringer Ingelheim Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria:
- Healthy males according to the investigator's assessment, as based on the following criteria: a complete medical history including a physical examination, vital signs (Blood Pressure,Pulse Rate), 12-lead electrocardiogram, and clinical laboratory tests
- Age 18 to 55 years (incl.)
- Body Mass Index 18.5 to 29.9 kg/m2 (incl.)
- Patients scheduled for removal of one mandibular third molar with partial or complete bony impaction. If medically indicated, the ipsilateral third molar in the upper jaw could also be removed;
- Surgery will be conducted under local anaesthesia using 12% lidocaine (with epinephrine). Intravenous sedations and general anaesthetics are not permitted.
- Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form
- Examined by the attending oral surgeon or physician and medically cleared to participate in the study
- Scheduled to undergo a qualifying surgical procedure
- Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation
Exclusion criteria:
- Any finding in the medical examination (including Blod Pressure, Pulse Rate or electrocardiogram) deviating from normal and judged clinically relevant by the investigator
- Repeated measurement of systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg
- Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- Any evidence of a concomitant disease judged clinically relevant by the investigator
- Acute local infection at the time of surgery that could confound the post-surgical evaluation
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of the gastrointestinal tract that could interfere with kinetics of the study drug(s)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: BI 1026706 low dose
|
Placebo to BI 1026706 solution
BI 1026706
Placebo to BI 1026706 tablet
|
|
Expérimental: BI 1026706 high dose
|
BI 1026706
Placebo to BI 1026706 tablet
|
|
Expérimental: Placebo reference
|
Placebo to BI 1026706 solution
Placebo to BI 1026706 tablet
|
|
Expérimental: Celecoxib reference
Celecoxib capsule
|
Placebo to BI 1026706 solution
Celecoxib capsule
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
SPID0-8h
Délai: up to 8 hours post drug administration
|
Time-weighted sum of pain intensity difference (PID) from 0 to 8 hours post drug administration (SPID0-8h).
SPID0-8h: possible range (-400; 800).
The greater SPID0-8 the greater the reduction of pain intensity over the first 8 hours post drug administration.
|
up to 8 hours post drug administration
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
TOTPAR0-8h
Délai: up to 8 hours post drug administration
|
Time-weighted total pain relief (PAR) from 0 to 8 hours (TOTPAR0-8h).
(TOTPAR0-8h)TOTPAR0-8h: possible range (0;32).
The greater TOTPAR0-8h the more pain relief was experienced over the first 8 hours post drug administration.
|
up to 8 hours post drug administration
|
|
SPID0-2h
Délai: up to 2 hours post drug administration
|
Time-weighted sum of PID from 0 to 2 hours (SPID0-2h).
SPID0-2h: possible range (-100; 200).
The greater SPID0-2 the greater the reduction of pain intensity over the first 2 hours post drug administration.
|
up to 2 hours post drug administration
|
|
Time to Meaningful Pain Relief
Délai: up to 10 hours post drug administration
|
Time to meaningful pain relief was captured by a stopwatch started by the trial staff immediately after administration of study medication and stopped by the subject as soon as a meaningful pain relief was felt by the subject. If a subject did not have any meaningful pain relief up to 10 h, the time was censored at 10 h. Kaplan-Meier estimates over time for each treatment and time to event endpoint 'Time to meaningful pain relief' were presented descriptively. |
up to 10 hours post drug administration
|
|
Time to First Dose of Rescue Medication
Délai: up to 10 hours post drug administration
|
The time to first dose of rescue medication was defined by the difference in time of the study drug intake and the time of first rescue medication use within the first 10 h after study drug administration. Kaplan-Meier estimates over time for each treatment and time to event endpoint 'Time to first dose of rescue medication' were presented descriptively. Subjects without intake of rescue medication within the first 10 hours after study drug administration were censored at 10 hours. |
up to 10 hours post drug administration
|
|
Percentage of Patients With Drug-related Adverse Events
Délai: From first drug administration until 3 days after last drug administration, upto 4 days
|
Percentage of patients with drug-related adverse events
|
From first drug administration until 3 days after last drug administration, upto 4 days
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Complications postopératoires
- La douleur
- Manifestations neurologiques
- Douleur, Postopératoire
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents du système nerveux périphérique
- Inhibiteurs d'enzymes
- Analgésiques
- Agents du système sensoriel
- Agents anti-inflammatoires non stéroïdiens
- Analgésiques, non narcotiques
- Agents anti-inflammatoires
- Agents antirhumatismaux
- Inhibiteurs de la cyclooxygénase
- Inhibiteurs de la cyclooxygénase 2
- Célécoxib
Autres numéros d'identification d'étude
- 1320.13
- 2013-003580-62 (Numéro EudraCT: EudraCT)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .